Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DocCheck AG's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 44.17.
DocCheck AG's Days Inventory for the
six
months ended in Dec. 2025 was 67.8.
DocCheck AG's Days Payable for the
six
months ended in Dec. 2025 was 48.41.
Therefore, DocCheck AG's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 63.56.
DocCheck AG (HAM:AJ91) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
DocCheck AG Cash Conversion Cycle Related Terms
DocCheck AG Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for DocCheck AG's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:AJ91 vs VEEV, BTSG, TEM: Cash Conversion Cycle Comparison
For the Health Information Services subindustry, DocCheck AG's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DocCheck AG Cash Conversion Cycle vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DocCheck AG's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where DocCheck AG's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
DocCheck AG's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DocCheck AG (HAM:AJ91) has a Cash Conversion Cycle of 63.56 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on DocCheck AG and its competitors.
Is DocCheck AG's Cash Conversion Cycle too high?
DocCheck AG's current Cash Conversion Cycle is 63.56. The Healthcare Providers & Services industry median Cash Conversion Cycle is 17.75. DocCheck AG's value of 63.56 is 258.1% above this industry median. Overall, DocCheck AG has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does DocCheck AG's Cash Conversion Cycle compare to VEEV and BTSG?
DocCheck AG's Cash Conversion Cycle of 63.56 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 17.75. DocCheck AG's value of 63.56 is 258.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 17.75, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DocCheck AG's current Cash Conversion Cycle of 63.56 is 258.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on DocCheck AG and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 17.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DocCheck AG's current Cash Conversion Cycle is 63.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DocCheck AG stock overvalued right now?
DocCheck AG (HAM:AJ91) has a current Cash Conversion Cycle of 63.56. The stock's GF Value™ is €9.52, compared to a current price of €11.90 — trading 25% above its estimated fair value. The current Cash Conversion Cycle is 63.56 and 258.1% above the Healthcare Providers & Services industry median of 17.75. DocCheck AG's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For DocCheck AG (HAM:AJ91), the current Cash Conversion Cycle is 63.56 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DocCheck AG (HAM:AJ91) Overvalued in 2026?
Based on GuruFocus' analysis, DocCheck AG stock appears to be overvalued.
The current stock price of €11.90 is trading 25% above its estimated GF Value™ of €9.52.
Key valuation signals for HAM:AJ91:
Cash Conversion Cycle: 63.56
GF Value™: €9.52 vs. price of €11.90 (25% above fair value)
Industry Position: 258.1% above the Healthcare Providers & Services median
No single metric tells the full story. See the HAM:AJ91 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DocCheck AG is a Germany-based company engaged in the healthcare sector. It operates through subsidiaries: antwerpes AG develops integrated communication concepts for the healthcare sector, including social media and digital communication with focus on e-marketing concepts, search engine optimization (SEO), search engine advertising (SEA) and search engine marketing (SEM); DocCheck Medical Services GmbH operates an online platform for healthcare professionals, such as physicians and pharmacists; DocCheck Medizinbedarf und Logistik GmbH wholesales medical products from third parties and also produces own medical products, and DocCheck Guano AG is a venture capital company with focus on e-health companies and promotes healthcare startups.
71GF Score
Get the complete analysis for HAM:AJ91
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:AJ91 has been successfully added to your 
